AMULET IDE STUDY – 3YR OUTCOMES

AMPLATZER™ AMULET™ LAA OCCLUDER DEMONSTRATES SAFETY AND EFFECTIVENESS THROUGH 3 YEARS

STROKES IN WATCHMAN‡ PATIENTS WERE MORE FREQUENTLY PRECEDED BY DEVICE-RELATED FACTORS (DEVICE-RELATED THROMBUS, DRT; OR PERI-DEVICE LEAK, PDL) THAN STROKES IN AMULET PATIENTS

Ischemic Stroke Patient Details (6 Months – 3 Years)*	Amulet (n=29)	Watchman‡ (n=29)
Device factors**		
Device-related thrombus	1	2
Peridevice leak (≥3mm)	3	15
OAC usage at time of stroke	0	3

* Aspirin only recommended for both groups after 6 months
** Device factors had to occur prior to the stroke occurrence to be counted
OAC - Oral Anticoagulation

BOTH CARDIOVASCULAR DEATH AND ALL-CAUSE DEATH TRENDED LOWER AT 3 YEARS WITH AMULET THAN WATCHMAN‡[1]

Cardiovascular Death



All-Cause Death



1. Descriptive analysis of non-powered endpoints in a population with differential long-term follow-up at 3 years

Lakkireddy et al. 3-Year Outcomes from the Amplatzer™ Amulet™ Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE), presented at TCT 2022.

Abbott
3200 Lakeside Dr., Santa Clara, CA. 95054 USA
www.structuralheart.abbott

Abbott